Amneal Lines Up Launches As It Builds Out Biosimilars Business
Generics Sales Remain Flat In Q3, But Alymsys Bevacizumab Biosimilar Makes Solid Start
Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.
